Previous close | 1,406.20 |
Open | 1,413.10 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 1,401.25 - 1,417.20 |
52-week range | 896.85 - 1,519.00 |
Volume | |
Avg. volume | 1,564,258 |
Market cap | 1.138T |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 30.67 |
EPS (TTM) | 45.94 |
Earnings date | 10 May 2024 |
Forward dividend & yield | 8.50 (0.60%) |
Ex-dividend date | 21 Jul 2023 |
1y target est | 1,406.41 |
Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.
Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products